Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr

The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024

Thyrocare Technologies posts Q4 FY24 consolidated PAT at Rs. 17.78 Cr

The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024

Gujarat Themis Biosyn posts Q4 FY24 PAT at Rs. 15.88 Cr

The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024

Merck discontinues Phase 3 KeyVibe-010 trial of coformulation of Vibostolimab and Pembrolizumab

Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria

Bayer Q1 2024 net income drops 8.2% to € 2 billion

EBITDA before special items falls 1.3 percent to € 4.41 billion

Coveris invests over €8 million in production capacity

Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany

Biocon signs supply deal with Medix for commercialization of generic Saxenda in Mexico

Moderna update on investigational RSV vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024

Sanofi India posts Q1 CY24 PAT at Rs. 136.6 Cr

Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets